GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Innovation1 Biotech Inc (OTCPK:IVBT) » Definitions » Cash Flow from Financing

Innovation1 Biotech (Innovation1 Biotech) Cash Flow from Financing : $0.51 Mil (TTM As of Aug. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Innovation1 Biotech Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Aug. 2023, Innovation1 Biotech paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, Innovation1 Biotech spent $0.00 Mil on financial activities for the three months ended in Aug. 2023.


Innovation1 Biotech Cash Flow from Financing Historical Data

The historical data trend for Innovation1 Biotech's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovation1 Biotech Cash Flow from Financing Chart

Innovation1 Biotech Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only 0.03 0.79 0.15 4.00 0.51

Innovation1 Biotech Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.05 0.25 0.21 -

Innovation1 Biotech Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Innovation1 Biotech's Cash from Financing for the fiscal year that ended in Aug. 2023 is calculated as:

Innovation1 Biotech's Cash from Financing for the quarter that ended in Aug. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Innovation1 Biotech  (OTCPK:IVBT) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Innovation1 Biotech's issuance of stock for the three months ended in Aug. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Innovation1 Biotech's repurchase of stock for the three months ended in Aug. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Innovation1 Biotech's net issuance of debt for the three months ended in Aug. 2023 was $0.00 Mil. Innovation1 Biotech received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Innovation1 Biotech's net issuance of preferred for the three months ended in Aug. 2023 was $0.00 Mil. Innovation1 Biotech paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Innovation1 Biotech's cash flow for dividends for the three months ended in Aug. 2023 was $0.00 Mil. Innovation1 Biotech received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Innovation1 Biotech's other financing for the three months ended in Aug. 2023 was $0.00 Mil. Innovation1 Biotech received $0.00 Mil on other financial activities.


Innovation1 Biotech Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Innovation1 Biotech's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Innovation1 Biotech (Innovation1 Biotech) Business Description

Traded in Other Exchanges
N/A
Address
40 Wall Street, Suite 2701, New York, NY, USA, 10005
Innovation1 Biotech Inc is a shell company.
Executives
Grays Peak Llc 10 percent owner 8 THE GREEN, STE. A, DOVER DE 19803
Timothy Orr director, 10 percent owner, officer: President 4010 TANAGER LANE, #A, MEAD WA 99021
Darren Long director, 10 percent owner, officer: CEO & Secretary 4010 TANAGER LANE, #A, MEAD WA 99021
Brian Martinho director, 10 percent owner, officer: Treasurer 4010 EAST TANAGER LANE, MEAD WA 99021